Pathology and immunopathology research最新文献

英文中文

Contents, Vol. 8, 1989 目录，第8卷，1989年

Pathology and immunopathology research

Pub Date : 1989-01-01 DOI: 10.1159/000157151

J. Talmadge, S. Cooper, A. Fraire, P. Buffler, D. Greenberg, Claire Langston, Robert E. Lewis, M. Brackin, J. Cruse, B. Brackin, D. Butkus, S. Raju, M. Crawford, R. Krueger, K. Kirchner, J. Bower, Y. Hayashi, C. Kurashima, T. Takemura, K. Hirokawa, V. Suphiphat, S. Riengropitak, S. Sahaphong, P. Newberne, R. W. Pryor, L. Hinshaw, J. Ware, S. Maygarden

引用次数: 0

Development of immunotherapeutic strategies for the treatment of malignant neoplasia. 恶性肿瘤免疫治疗策略的发展。

Pathology and immunopathology research

Pub Date : 1989-01-01 DOI: 10.1159/000157155

J E Talmadge

The utility of biologics and BRMs in cancer therapeutics can be considered with a cautious optimism predicated on the progress that has occurred to date and the specific indications that can now be identified. Although to date BRMs have shown only limited activity in restricted subsets of patients which may be viewed as dissuasion to some investigators; nonetheless, it should also be a stimulus to conduct careful, basic, and clinical experimentation aimed at verifying the promise from preclinical studies and to obtain further fundamental information on the BRM mechanism of action that would provide a basis for the ultimate utilization of these agents as well as the identification-development of appropriate analogs predicted on the deficiencies observed to date with the BRM.

生物制剂和brm在癌症治疗中的应用可以谨慎乐观地考虑到迄今为止已经发生的进展和现在可以确定的具体适应症。尽管迄今为止，BRMs仅在有限的患者亚群中显示出有限的活性，这可能被一些研究人员视为劝阻;尽管如此，这也应该是一种刺激，以进行仔细的、基础的和临床的实验，旨在验证临床前研究的前景，并获得关于BRM作用机制的进一步基础信息，这些信息将为这些药物的最终利用提供基础，以及根据迄今为止观察到的BRM的缺陷，识别和开发合适的类似物。

引用次数: 3

Epidemiologic aspects of childhood mesothelioma. 儿童间皮瘤的流行病学研究。

Pathology and immunopathology research

Pub Date : 1989-01-01 DOI: 10.1159/000157156

S P Cooper, A E Fraire, P A Buffler, S D Greenberg, C Langston

Our calculation provides the first population-based incidence rate of childhood mesothelioma in the United States. Based on these data and on our pathology review, we conclude that mesothelioma occurs rarely in children and that this diagnosis is difficult to establish. A more systematic approach to identifying mesothelioma cases in children, as well as adults, will be facilitated by increasing state surveillance of cancer incidence and by the proposed addition of a unique code for mesothelioma in the Tenth Revision of the ICD. There is a critical need for histopathological verification of mesothelioma cases. The increased use of a uniform, reproducible histopathologic classification and mesothelioma panels should address this problem. A thorough microscopic study of individual cases needs to be supplemented by a careful assessment of the clinical findings and environmental factors. The available data thus far do not support an association between childhood mesothelioma and asbestos exposure. However, the ubiquitous nature of asbestos exposures, the known association of asbestos with adult mesothelioma, the unreliability of the diagnosis, and the lack of adequate data regarding asbestos exposures, all indicate that asbestos involvement cannot be categorically ruled out, especially in older children with the potential for a longer duration of exposure and a plausible induction period. Mesothelioma in children, as well as in adults, is likely to have a multifactorial etiology. Radiation, prenatal medications, and genetic factors are all possible etiologic agents in childhood mesothelioma. In addition, other, as of yet unspecified environmental factors may play a role in this disease. When cases are diagnosed, the physician should inquire about the history of exposure to asbestos or other hazardous materials in the patient's environment, prior radiation exposure, medication exposure pre- and postnatally, prior cancer diagnoses, and a family history of cancer. An interdisciplinary approach, combining the diagnostic skills of the pathologist and the analytic skills of the epidemiologist, will be of value and of special relevance in the study of mesotheliomas.

我们的计算提供了美国第一个基于人群的儿童间皮瘤发病率。基于这些数据和我们的病理回顾，我们得出结论，间皮瘤在儿童中很少发生，这种诊断很难建立。通过加强国家对癌症发病率的监测，以及拟议在《国际疾病分类》第十版中增加一种独特的间皮瘤编码，将有助于采用一种更系统的方法来识别儿童和成人间皮瘤病例。对间皮瘤病例进行组织病理学检查是非常必要的。增加使用统一的、可重复的组织病理学分类和间皮瘤小组应该解决这个问题。对个别病例进行彻底的显微镜研究需要辅以对临床表现和环境因素的仔细评估。到目前为止，现有的数据并不支持儿童间皮瘤与石棉接触之间的联系。然而，石棉暴露的普遍性质、石棉与成人间皮瘤的已知关联、诊断的不可靠性以及缺乏关于石棉暴露的充分数据，都表明不能绝对排除石棉的参与，特别是在年龄较大的儿童中，可能有更长的暴露时间和可能的诱发期。儿童间皮瘤，以及在成人，可能有一个多因素的病因。辐射、产前药物治疗和遗传因素都可能是儿童间皮瘤的病因。此外，其他尚未确定的环境因素也可能在该病中起作用。确诊病例时，医生应询问患者在环境中接触石棉或其他有害物质的历史，既往的辐射暴露，产前和产后的药物暴露，既往的癌症诊断和癌症家族史。结合病理学家的诊断技能和流行病学家的分析技能的跨学科方法，将在间皮瘤的研究中具有价值和特殊的相关性。

{"title":"Epidemiologic aspects of childhood mesothelioma.","authors":"S P Cooper, A E Fraire, P A Buffler, S D Greenberg, C Langston","doi":"10.1159/000157156","DOIUrl":"https://doi.org/10.1159/000157156","url":null,"abstract":"<p><p>Our calculation provides the first population-based incidence rate of childhood mesothelioma in the United States. Based on these data and on our pathology review, we conclude that mesothelioma occurs rarely in children and that this diagnosis is difficult to establish. A more systematic approach to identifying mesothelioma cases in children, as well as adults, will be facilitated by increasing state surveillance of cancer incidence and by the proposed addition of a unique code for mesothelioma in the Tenth Revision of the ICD. There is a critical need for histopathological verification of mesothelioma cases. The increased use of a uniform, reproducible histopathologic classification and mesothelioma panels should address this problem. A thorough microscopic study of individual cases needs to be supplemented by a careful assessment of the clinical findings and environmental factors. The available data thus far do not support an association between childhood mesothelioma and asbestos exposure. However, the ubiquitous nature of asbestos exposures, the known association of asbestos with adult mesothelioma, the unreliability of the diagnosis, and the lack of adequate data regarding asbestos exposures, all indicate that asbestos involvement cannot be categorically ruled out, especially in older children with the potential for a longer duration of exposure and a plausible induction period. Mesothelioma in children, as well as in adults, is likely to have a multifactorial etiology. Radiation, prenatal medications, and genetic factors are all possible etiologic agents in childhood mesothelioma. In addition, other, as of yet unspecified environmental factors may play a role in this disease. When cases are diagnosed, the physician should inquire about the history of exposure to asbestos or other hazardous materials in the patient's environment, prior radiation exposure, medication exposure pre- and postnatally, prior cancer diagnoses, and a family history of cancer. An interdisciplinary approach, combining the diagnostic skills of the pathologist and the analytic skills of the epidemiologist, will be of value and of special relevance in the study of mesotheliomas.</p>","PeriodicalId":77765,"journal":{"name":"Pathology and immunopathology research","volume":"8 5-6","pages":"276-86"},"PeriodicalIF":0.0,"publicationDate":"1989-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000157156","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13840740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Therapeutic and toxic activity of tumor necrosis factor is synergistic with gamma interferon. 肿瘤坏死因子的治疗和毒性活性与γ干扰素具有协同作用。

Pathology and immunopathology research

Pub Date : 1989-01-01 DOI: 10.1159/000157135

J E Talmadge, O Bowersox, H Tribble, M Shepard, D Liggitt

引用次数: 14

Ultrastructural immunogold labeling patterns--image processing, mapping and quantitative microanalysis of antigenic sites in renal biopsies and neoplasms. 超微结构免疫金标记模式——肾活检和肿瘤中抗原位点的图像处理、制图和定量微分析。

Pathology and immunopathology research

Pub Date : 1989-01-01 DOI: 10.1159/000157137

G A Herrera, R L Lott, P W Sanders, T Stark, J T Mastovich

引用次数: 7

Ontogenic development of the secretory immune system in human fetal salivary glands. 人胎儿唾液腺分泌免疫系统的个体发育。

Pathology and immunopathology research

Pub Date : 1989-01-01 DOI: 10.1159/000157159

Y Hayashi, C Kurashima, T Takemura, K Hirokawa

引用次数: 16

Sepsis/septic shock in adults and children. 成人和儿童败血症/感染性休克。

Pathology and immunopathology research

Pub Date : 1989-01-01 DOI: 10.1159/000157153

R W Pryor, L B Hinshaw

引用次数: 2

Long-term bone marrow cultures: recent studies with clonal hematopoietic and stromal cell lines. 长期骨髓培养:克隆造血和基质细胞系的最新研究。

Pathology and immunopathology research

Pub Date : 1989-01-01 DOI: 10.1159/000157134

M Ohta, P Anklesaria, T J FitzGerald, K Kase, J Leif, J Delamarter, N Farber, E Wright, J S Greenberger

引用次数: 10

Nutritional effects on hematological and immunological responses of mice exposed to diacetoxyscirpenol (DAS). 营养对双乙酰氧基哌嗪醇(DAS)小鼠血液学和免疫反应的影响。

Pathology and immunopathology research

Pub Date : 1989-01-01 DOI: 10.1159/000157160

V S Suphiphat, S Riengropitak, S Sahaphong, P M Newberne

引用次数: 2

The role of endothelium in leukocytes emigration: the views of Cohnheim, Metchnikoff and their contemporaries. 内皮在白细胞迁移中的作用:Cohnheim, Metchnikoff和他们同时代人的观点。

Pathology and immunopathology research

Pub Date : 1989-01-01 DOI: 10.1159/000157136

H Z Movat

引用次数: 6

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Pathology and immunopathology research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀